Colette Owens

1.2k total citations
22 papers, 233 citations indexed

About

Colette Owens is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Colette Owens has authored 22 papers receiving a total of 233 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 8 papers in Genetics. Recurrent topics in Colette Owens's work include Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Viral-associated cancers and disorders (5 papers). Colette Owens is often cited by papers focused on Lymphoma Diagnosis and Treatment (16 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Viral-associated cancers and disorders (5 papers). Colette Owens collaborates with scholars based in United States, Israel and Germany. Colette Owens's co-authors include Deaglan Joseph McHugh, Chung‐Han Lee, David H. Aggen, Robert J. Motzer, Darren R. Feldman, Ritesh R. Kotecha, Maria I. Carlo, Ying‐Bei Chen, Neil J. Shah and Martin H. Voss and has published in prestigious journals such as Journal of Clinical Oncology, Blood and European Urology.

In The Last Decade

Colette Owens

20 papers receiving 229 citations

Peers

Countries citing papers authored by Colette Owens

Since Specialization

Citations

This map shows the geographic impact of Colette Owens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Colette Owens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Colette Owens more than expected).

Fields of papers citing papers by Colette Owens

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Colette Owens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Colette Owens. The network helps show where Colette Owens may publish in the future.

Co-authorship network of co-authors of Colette Owens

This figure shows the co-authorship network connecting the top 25 collaborators of Colette Owens. A scholar is included among the top collaborators of Colette Owens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Colette Owens. Colette Owens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel devimistat results in complete remissions in heavily pretreated Burkitt lymphoma in a phase 2 trial 2025 ·Blood Advances ·Raphaël Steiner, Liana Nikolaenko, Ranjit Nair, Venkatraman Seshan, (unknown), Niloufer Khan, Jeremy S. Abramson, Steven M. Horwitz, Matthew J. Matasar, Colette Owens, (unknown), (unknown), Timothy S. Pardee, (unknown), (unknown), (unknown), Shreya Vemuri, Ariela Noy	0
2	Two decades of single-institution data reveal rare long-term survivors of relapsed/refractory Burkitt lymphoma 2025 ·Haematologica ·(unknown), (unknown), Ellin Berman, Philip Caron, Lorenzo Falchi, Paul A. Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, Anita J. Kumar, Jennifer Kimberly Lue, Alison J. Moskowitz, Colette Owens, Maria Lia Palomba, Parastoo B. Dahi, Gilles Salles, Santosha A. Vardhana, Gunjan L. Shah, Andrew D. Zelenetz, William T. Johnson, Ariela Noy	0
3	Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial 2024 ·European Urology ·Kelly N. Fitzgerald, Chung‐Han Lee, Martin H. Voss, Maria I. Carlo, Andrea Knežević, (unknown), Ying‐Bei Chen, Robert A. Lefkowitz, Neil J. Shah, Colette Owens, Deaglan Joseph McHugh, David H. Aggen, (unknown), Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer	15
4	CD5 expression in marginal zone lymphoma does not predict inferior outcome and has similarities to indolent lymphomas 2024 ·PubMed ·Paola Ghione, (unknown), Erel Joffe, M. Lia Palomba, Ariela Noy, Philip Caron, Paul A. Hamlin, Anita Kumar, Matthew J. Matasar, Colette Owens, Alison J. Moskowitz, Lorenzo Falchi, David J. Straus, Steven M. Horwitz, Gilles Salles, Ahmet Doǧan, Andrew D. Zelenetz	1
5	Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Updated results from a phase 2 trial. 2023 ·Journal of Clinical Oncology ·Chung‐Han Lee, Kelly N. Fitzgerald, Martin H. Voss, Maria I. Carlo, Andrea Knežević, (unknown), Ying‐Bei Chen, Mark Zucker, Robert A. Lefkowitz, (unknown), Neil J. Shah, Colette Owens, Deaglan Joseph McHugh, David H. Aggen, (unknown), Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer	3
6	Subcutaneous (SC) Mosunetuzumab (mosun) As First-Line Therapy for Patients (pts) with High Tumor-Burden Follicular Lymphoma (FL): First Results of a Multicenter Phase 2 Study 2023 ·Blood ·Lorenzo Falchi, (unknown), Paola Ghione, Colette Owens, Paul A. Hamlin, Jennifer Kimberly Lue, Zachary D. Epstein‐Peterson, Maria Lia Palomba, Anita Kumar, Pallawi Torka, Lori A. Leslie, (unknown), (unknown), Lauren Wood, (unknown), (unknown), Santosha A. Vardhana, Andrew D. Zelenetz, Gilles Salles	13
7	Phase II Trial of Cabozantinib Plus Nivolumab in Patients With Non–Clear-Cell Renal Cell Carcinoma and Genomic Correlates 2022 ·Journal of Clinical Oncology ·Chung‐Han Lee, Martin H. Voss, Maria I. Carlo, Ying‐Bei Chen, Mark Zucker, Andrea Knežević, Robert A. Lefkowitz, Natalie Shapnik, (unknown), Ed Reznik, Neil J. Shah, Colette Owens, Deaglan Joseph McHugh, David H. Aggen, (unknown), Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer	105
8	A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma 2022 ·Blood Advances ·David Qualls, (unknown), Karissa Whiting, Anita Kumar, Matthew J. Matasar, Colette Owens, Chelsea Nichols, (unknown), (unknown), (unknown), (unknown), Venkatraman Seshan, Gilles Salles, Anas Younes, Connie Lee Batlevi	3
9	Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma 2021 ·Haematologica ·Richard J. Lin, Colette Owens, Esther Drill, (unknown), (unknown), (unknown), Ariela Noy, John F. Gerecitano, Pamela Drullinsky, Philip Caron, Anita J. Kumar, Matthew J. Matasar, Craig H. Moskowitz, Beatriz Korc‐Grodzicki, Andrew D. Zelenetz, Gilles Salles, Paul A. Hamlin	4
10	Successful implementation of outpatient R ± DHAX (rituximab, dexamethasone, oxaliplatin, cytarabine) for select patients with lymphoma: a single-center experience 2021 ·Leukemia & lymphoma ·(unknown), (unknown), Michael J. Buege, Phuong Dao, (unknown), (unknown), (unknown), Philip Caron, Lorenzo Falchi, Paul A. Hamlin, Audrey Hamilton, Matthew J. Matasar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Gottfried von Keudell, Anas Younes, Andrew D. Zelenetz, Anita Kumar	1
11	Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial. 2021 ·Journal of Clinical Oncology ·Chung‐Han Lee, Martin H. Voss, Maria I. Carlo, Ying‐Bei Chen, Eduard Reznik, Andrea Knežević, Robert A. Lefkowitz, Natalie Shapnik, (unknown), (unknown), Neil J. Shah, Colette Owens, Deaglan Joseph McHugh, David H. Aggen, (unknown), Ritesh R. Kotecha, Darren R. Feldman, Robert J. Motzer	28
12	Initial results of a multicenter, investigator initiated study of MRD driven time limited therapy with zanubrutinib, obinutuzumab, and venetoclax. 2020 ·Journal of Clinical Oncology ·Jacob D. Soumerai, Anthony R. Mato, Jason Carter, Ahmet Doǧan, Ephraim P. Hochberg, Jeffrey A. Barnes, (unknown), Jeremy S. Abramson, Connie Lee Batlevi, Erel Joffe, Matthew J. Matasar, Ariela Noy, Colette Owens, Maria Lia Palomba, Tak Takvorian, K. T. Flaherty, (unknown), Lindsey E. Roeker, Omar Abdel‐Wahab, Andrew D. Zelenetz	15
13	CD5-Positive Marginal Zone Lymphoma: Clinical Characteristics of the MSKCC Cohort, and Comparison with the CD5-Negative Population 2020 ·Blood ·Paola Ghione, (unknown), Erel Joffe, M. Lia Palomba, Ariela Noy, Matthew J. Matasar, Philip Caron, Audrey Hamilton, Paul A. Hamlin, Anita Kumar, Colette Owens, Alison J. Moskowitz, Lorenzo Falchi, Gottfried von Keudell, (unknown), David J. Straus, Steven M. Horwitz, Ahmet Doǧan, Andrew D. Zelenetz	3
14	Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma 2019 ·Blood ·Sven Borchmann, Erel Joffe, Craig H. Moskowitz, Andrew D. Zelenetz, Ariela Noy, Carol S. Portlock, John F. Gerecitano, Connie Lee Batlevi, Philip Caron, Pamela Drullinsky, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Colette Owens, M. Lia Palomba, Anas Younes, David J. Straus	26
15	Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era 2019 ·Blood ·Sabela Bobillo, Erel Joffe, Venkatraman Seshan, Ariela Noy, Steven M. Horwitz, M. Lia Palomba, Matthew J. Matasar, David J. Straus, Paul A. Hamlin, Connie Lee Batlevi, Paola Ghione, David Sermer, Alison J. Moskowitz, Audrey Hamilton, Philip Caron, Colette Owens, (unknown), Ahmet Doǧan, Andrew D. Zelenetz, Anas Younes	1
16	Initial Results of a Phase II Study of Sequential Chemotherapy and Lenalidomide Followed By Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma 2018 ·Blood ·Anita Kumar, Andrew D. Zelenetz, Connie Lee Batlevi, Philip Caron, Ahmet Doǧan, Pamela Drullinsky, John F. Gerecitano, Audrey Hamilton, Paul A. Hamlin, (unknown), Matthew J. Matasar, Susan J. McCall, Alison J. Moskowitz, Craig H. Moskowitz, Colette Owens, Janine Pichardo, Heiko Schöder, (unknown), David J. Straus, Anas Younes	1
17	Active Surveillance for Newly Diagnosed Nodular Lymphocyte-Predominant Hodgkin Lymphoma 2017 ·Blood ·Sven Borchmann, Erel Joffe, Craig H. Moskowitz, Andrew D. Zelenetz, Ariela Noy, Carol S. Portlock, John F. Gerecitano, Connie Lee Batlevi, Philip Caron, Pamela Drullinsky, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Colette Owens, Lia Palomba, Anas Younes, David J. Straus	1
18	Effect of prednisone and rituximab prephase on early toxicity in older DLBCL patients (pts) receiving RCHOP within a NHL specific comprehensive geriatric assessment (CGA) trial. 2015 ·Journal of Clinical Oncology ·Colette Owens, (unknown), John F. Gerecitano, Matthew J. Matasar, Ariela Noy, Craig H. Moskowitz, Pamela Drullinsky, Maria Lia Palomba, David J. Straus, Steven M. Horwitz, Andrew D. Zelenetz, Carol S. Portlock, Anita Kumar, Paul A. Hamlin	3
19	Dose-Adjusted EPOCH +/- Rituximab in Older Patients with High Grade Diffuse Large B-Cell Lymphoma, Burkitt and T-Cell Lymphoma: An Effective Regimen with Acceptable Toxicity Profile 2014 ·Blood ·Colette Owens, Jocelyn Migliacci, Steven M. Horwitz, Matthew J. Matasar, Alison J. Moskowitz, Ariela Noy, Maria Lia Palomba, Carol S. Portlock, David J. Straus, Anas Younes, Andrew D. Zelenetz, Paul A. Hamlin	1
20	An update on the management of peripheral T-cell lymphoma and emerging treatment options 2011 ·Journal of Blood Medicine ·Adrienne A. Phillips, Colette Owens, Sang‐Min Lee, Govind Bhagat	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact